Skip to main content Accessibility help

We use cookies to distinguish you from other users and to provide you with a better experience on our websites. Close this message to accept cookies or find out how to manage your cookie settings.

Close cookie message
×
Hostname: page-component-cd9895bd7-q99xh Total loading time: 0 Render date: 2024-12-26T15:47:19.815Z Has data issue: false hasContentIssue false

Disorders of the Neuromuscular Junction

from Part II - Neuromuscular Cases

Published online by Cambridge University Press:  29 November 2024

Jessica E. Hoogendijk ,
Marianne de Visser ,
Pieter A. van Doorn  and
Erik H. Niks
Jessica E. Hoogendijk
Affiliation:
University Medical Center Utrecht
Marianne de Visser
Affiliation:
Amsterdam University Medical Center
Pieter A. van Doorn
Affiliation:
Erasmus MC, University Medical Center, Rotterdam
Erik H. Niks
Affiliation:
Leiden University Medical Center
Get access
Type
Chapter
Information
Neuromuscular Disease
A Case-Based Approach
 , pp. 156 - 171
Publisher: Cambridge University Press
Print publication year: 2024

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

Suggested Reading

Doughty, CT, Guidon, AC. Diagnostic testing for ocular myasthenia gravis: stronger together. Neurology 2020;95(13):563–564. doi: 10.1212/WNL.0000000000010616. Epub 2020 Aug 11. PMID: 32788244.Google Scholar
Gilhus, NE. Myasthenia gravis can have consequences for pregnancy and the developing child. Front Neurol 2020;11:554. doi: 10.3389/fneur.2020.00554. PMID: 32595594; PMCID: PMC7304249.Google Scholar
Gilhus, NE, Tzartos, S, Evoli, A, et al. Myasthenia gravis. Nat Rev Dis Primers 2019;5(1):30. doi: 10.1038/s41572-019-0079-y. PMID: 31048702.Google Scholar
Menon, D, Bril, V. Pharmacotherapy of generalized myasthenia gravis with special emphasis on newer biologicals. Drugs 2022;82(8):865–887. doi: 10.1007/s40265-022-01726-y. Epub 2022 May 31. PMID: 35639288; PMCID: PMC9152838.Google Scholar
Narayanaswami, P, Sanders, DB, Wolfe, G, et al. International consensus guidance for management of myasthenia gravis: 2020 Update. Neurology 2021;96(3):114–122. doi: 10.1212/WNL.0000000000011124. Epub 2020 Nov 3. PMID: 33144515; PMCID: PMC7884987.Google Scholar
Vanoli, F, Mantegazza, R. Current drug treatment of myasthenia gravis. Curr Opin Neurol 2023;36(5):410–415. doi: 10.1097/WCO.0000000000001196. Epub 2023 Aug 30. PMID: 37678337.Google Scholar
Verschuuren, JJ, Palace, J, Murai, H, et al. Advances and ongoing research in the treatment of autoimmune neuromuscular junction disorders. Lancet Neurol 2022;21(2):189–202. doi: 10.1016/S1474-4422(21)00463-4. Erratum in: Lancet Neurol 2022 Mar;21(3):e3. PMID: 35065041.Google Scholar

Suggested Reading

Brauner, S, Eriksson-Dufva, A, Hietala, MA, et al. Comparison between rituximab treatment for new-onset generalized myasthenia gravis and refractory generalized myasthenia gravis. JAMA Neurol 2020;77:974–981. doi: 10.1001/jamaneurol.2020.0851.Google Scholar
Gilhus, NE. Myasthenia gravis can have consequences for pregnancy and the developing child. Front Neurol 2020 Jun 12;11:554. doi: 10.3389/fneur.2020.00554. PMID: 32595594; PMCID: PMC7304249.Google Scholar
Cao, M, Koneczny, I, Vincent, A. Myasthenia gravis with antibodies against muscle specific kinase: an update on clinical features, pathophysiology and treatment. Front Mol Neurosci 2020;13:159. doi: 10.3389/fnmol.2020.00159Google Scholar
Narayanaswami, P, Sanders, DB, Wolfe, G, et al. International consensus guidance for management of myasthenia gravis: 2020 update. Neurology 2021;96:114–122. doi:10.1212/WNL.0000000000011124Google Scholar
Verschuuren, JJ, Palace, J, Murai, H, et al. Advances and ongoing research in the treatment of autoimmune neuromuscular junction disorders. Lancet Neurol 2022;21(2):189–202. doi: 10.1016/S1474-4422(21)00463-4. Erratum in: Lancet Neurol. 2022 Mar;21(3):e3. PMID: 35065041.Google Scholar

Suggested Reading

Astaras, C, de Micheli, R, Moura, B, Hundsberger, T, Hottinger, AF. Neurological adverse events associated with immune checkpoint inhibitors: diagnosis and management. Curr Neurol Neurosci Rep 2018;18(1):3. doi: 10.1007/s11910-018-0810-1. PMID: 29392441.Google Scholar
Huang, YT, Chen, YP, Lin, WC, Su, WC, Sun, YT. Immune checkpoint inhibitor-induced myasthenia gravis. Front Neurol 2020;11:634. doi: 10.3389/fneur.2020.00634. PMID: 32765397; PMCID: PMC7378376.Google Scholar
Narayanaswami, P, Sanders, DB, Wolfe, G, et al. International consensus guidance for management of myasthenia gravis: 2020 Update. Neurology 2021;96(3):114–122. doi: 10.1212/WNL.0000000000011124. Epub 2020 Nov 3. PMID: 33144515; PMCID: PMC7884987.Google Scholar
Rossi, S, Gelsomino, F, Rinaldi, R, et al. Peripheral nervous system adverse events associated with immune checkpoint inhibitors. J Neurol 2023;270(6):2975–2986. doi: 10.1007/s00415-023-11625-1. Epub 2023 Feb 17. PMID: 36800019; PMCID: PMC10188572.Google Scholar
Safa, H, Johnson, DH, Trinh, VA, et al. Immune checkpoint inhibitor related myasthenia gravis: single center experience and systematic review of the literature. J Immunother Cancer 2019;7(1):319. doi: 10.1186/s40425-019-0774-y. PMID: 31753014; PMCID: PMC6868691.Google Scholar
Schneider, BJ, Naidoo J, Santomasso BD et al. Management of Immune-Related Adverse Events in Patients Treated With Immune Checkpoint Inhibitor Therapy: ASCO Guideline Update. J Clin Oncol. 2021 Dec 20;39(36):4073–4126. doi: 10.1200/JCO.21.01440. Epub 2021 Nov 1. Erratum in: J Clin Oncol. 2022 Jan 20;40(3):315. PMID: 34724392.Google Scholar

Suggested Reading

Huijbers, MG, Marx, A, Plomp, JJ, et al. Advances in the understanding of disease mechanisms of autoimmune neuromuscular junction disorders. Lancet Neurol 2022;21(2):163–175. doi: 10.1016/S1474-4422(21)00357-4. PMID: 35065039.Google Scholar
Kesner, VG, Oh, SJ, Dimachkie, MM, Barohn, RJ. Lambert-Eaton myasthenic syndrome. Neurol Clin 2018;36(2):379–394. doi: 10.1016/j.ncl.2018.01.008. PMID: 29655456; PMCID: PMC6690495.Google Scholar
Titulaer, MJ, Lang, B, Verschuuren, JJ. Lambert-Eaton myasthenic syndrome: from clinical characteristics to therapeutic strategies. Lancet Neurol 2011;10(12):1098–1107. doi: 10.1016/S1474-4422(11)70245-9. PMID: 22094130.Google Scholar
Titulaer, MJ, Maddison, P, Sont, JK, et al. Clinical Dutch-English Lambert-Eaton myasthenic syndrome (LEMS) tumor association prediction score accurately predicts small-cell lung cancer in the LEMS. J Clin Oncol 2011;29(7):902–908. doi: 10.1200/JCO.2010.32.0440. Epub 2011 Jan 18. PMID: 21245427.Google Scholar
Verschuuren, JJ, Palace, J, Murai, H, et al. Advances and ongoing research in the treatment of autoimmune neuromuscular junction disorders. Lancet Neurol 2022;21(2):189–202. doi: 10.1016/S1474-4422(21)00463-4. Erratum in: Lancet Neurol. 2022 Mar;21(3):e3. PMID: 35065041.Google Scholar

Suggested Reading

Finlayson, S, Morrow, JM, Rodriguez Cruz, PM, et al. Muscle magnetic resonance imaging in congenital myasthenic syndromes. Muscle Nerve 2016;54(2):211–219. doi: 10.1002/mus.25035. Epub 2016 Feb 22. PMID: 26789134; PMCID: PMC4982021.Google Scholar
Kao, JC, Milone, M, Selcen, D, et al. Congenital myasthenic syndromes in adult neurology clinic: a long road to diagnosis and therapy. Neurology 2018;91(19):e1770–e1777. doi: 10.1212/WNL.0000000000006478. Epub 2018 Oct 5. PMID: 30291185; PMCID: PMC6251603.Google Scholar
Ohno, K, Ohkawara, B, Shen, XM, Selcen, D, Engel, AG. Clinical and pathologic features of congenital myasthenic syndromes caused by 35 genes-a comprehensive review. Int J Mol Sci 2023;24(4):3730. doi: 10.3390/ijms24043730. PMID: 36835142; PMCID: PMC9961056.Google Scholar
Ramdas, S, Beeson, D. Congenital myasthenic syndromes: where do we go from here? Neuromuscul Disord 2021;31(10):943–954. doi: 10.1016/j.nmd.2021.07.400. PMID: 34736634.Google Scholar

Save book to Kindle

To save this book to your Kindle, first ensure no-reply@cambridge.org is added to your Approved Personal Document E-mail List under your Personal Document Settings on the Manage Your Content and Devices page of your Amazon account. Then enter the ‘name’ part of your Kindle email address below. Find out more about saving to your Kindle.

Note you can select to save to either the @free.kindle.com or @kindle.com variations. ‘@free.kindle.com’ emails are free but can only be saved to your device when it is connected to wi-fi. ‘@kindle.com’ emails can be delivered even when you are not connected to wi-fi, but note that service fees apply.

Find out more about the Kindle Personal Document Service.

Available formats
×

Save book to Dropbox

To save content items to your account, please confirm that you agree to abide by our usage policies. If this is the first time you use this feature, you will be asked to authorise Cambridge Core to connect with your account. Find out more about saving content to Dropbox.

Available formats
×

Save book to Google Drive

To save content items to your account, please confirm that you agree to abide by our usage policies. If this is the first time you use this feature, you will be asked to authorise Cambridge Core to connect with your account. Find out more about saving content to Google Drive.

Available formats
×